Matthew Levy, MD
Endocrinology, Diabetes & Metabolism · Kernersville, NCNPI 1255481180
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,614 of the $150,167 with a category attached, or 92.3%. Novo Nordisk accounts for 98.9% of it on its own, with 15 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $655.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$149K
- Lilly USA, LLC$220
- Sanofi-aventis U.S. LLC$178
- Insulet Corporation$152
- Bayer$125
- Ascendis Pharma Endocrinology Inc$125
- plus $822 from 10 others
What the payments were for
- Speaking & faculty fees$138,61492%
- Travel & lodging$5,7564%
- Food & beverage$5,6044%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 195 | $148,546 |
| Lilly USA, LLC | 4 | $220 |
| Sanofi-aventis U.S. LLC | 7 | $178 |
| Insulet Corporation | 3 | $152 |
| Bayer | 3 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Abbott | 4 | $124 |
| AbbVie | 1 | $120 |
| Boehringer Ingelheim | 1 | $120 |
| BETA Bionics, Inc. | 1 | $114 |
| Medtronic(2 entities) | 2 | $103 |
| Amgen | 1 | $90 |
| Sequel Med Tech, LLC | 2 | $55 |
| Valeritas, Inc. | 2 | $43 |
| Corcept Therapeutics | 1 | $31 |
| Cequr Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$59,300
- RYBELSUS$49,260
- Tresiba$13,857
- Xultophy 100/3.6$7,330
- iLet Bionic Pancreas$342
- Yorvipath$125
- Synthroid$120
- JARDIANCE$120
- Omnipod$107
- BAQSIMI$100
How this compares
$150,167 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 406 | $592,086 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 111 | $124,016 |
| Tresiba Flextouch U-200Insulin Degludec | 119 | $104,835 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 62 | $103,600 |
| JardianceEmpagliflozin | 86 | $96,492 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $93,010 |
| MounjaroTirzepatide | 69 | $84,367 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 95 | $81,523 |
| TrulicityDulaglutide | 64 | $78,094 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $50,510 |
| Xigduo XrDapaglifloz Propaned/Metformin | 64 | $48,931 |
| RybelsusSemaglutide | 45 | $46,866 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 29 | $33,562 |
| SynjardyEmpagliflozin/Metformin Hcl | 34 | $32,090 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $25,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $148,546 | $751,999553 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi, Tradjenta | $120 | $237,289261 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $220 | $170,150166 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $178 | $124,016111 claims |
| AbbVieSynthroid | $120 | $5,06161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Kernersville
- John LambethKernersville$25K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.